Reuters logo
BRIEF-Sarepta Therapeutics announces EMA validation of Eteplirsen
December 19, 2016 / 10:52 PM / a year ago

BRIEF-Sarepta Therapeutics announces EMA validation of Eteplirsen

Dec 19 (Reuters) - Sarepta Therapeutics Inc :

* Sarepta Therapeutics announces EMA validation of Eteplirsen authorization application for treatment of Duchenne muscular Dystrophy amenable to exon skipping 51

* Sarepta Therapeutics Inc - Sarepta is seeking conditional approval of Eteplirsen in EU through centralized procedure Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below